A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.
about
Resection versus other treatments for locally advanced pancreatic cancerGemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.The Role of End-of-Life Issues in the Design and Reporting of Cancer Clinical Trials: A Structured Literature ReviewPhase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trialsGemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer.Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signalingS-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.S-1 in the treatment of pancreatic cancer.Frankincense essential oil prepared from hydrodistillation of Boswellia sacra gum resins induces human pancreatic cancer cell death in cultures and in a xenograft murine model.Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma.Phase II clinical trials on investigational drugs for the treatment of pancreatic cancersPrognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy.Emerging insights into barriers to effective brain tumor therapeutics.S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis.Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy.The Role of Consolidation Chemo-Radiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis.A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study.Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer.A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.Pancreatic Cancer Chemoresistance to Gemcitabine.Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
P2860
Q24200227-11006BB6-DD77-446F-85E5-A033357B4B57Q26786174-55188CEC-8B11-4FDB-99CD-AA8F98A30ECDQ26795613-47FFDB4F-197E-4111-95B6-87E0BE197A5CQ30313606-30573714-CC1D-4A20-BA6C-4B9CE1D114C6Q33407858-02E44FFA-08FB-4051-957A-D5C8B3059B8AQ33412001-F6DC5ED0-7B60-46E5-9F35-A89CAADC8EB4Q33416894-D8F3A8E8-7882-41CA-8862-4404FFB8E182Q33421322-644D21F6-8C2F-460D-8BFA-8B336BE809BDQ33427177-3DC4A87C-E93C-4B2C-B173-D53476AC4951Q33440500-757BB5D6-E554-46EF-B9F2-C632815F589AQ33441606-AFD3AE3B-229B-42DA-A6B3-3B7B44EFDFC7Q33442676-3DF98F3F-54B6-40AB-8F55-53E95432A06DQ34294011-D0B95818-47F8-4A92-9AAA-3812CC91D189Q34305783-947E5190-4E23-4F13-AAD2-600FEAE0C3FCQ34326711-AC66D716-E716-4430-A18C-99DDCA5659B1Q34467156-736F5E90-160A-443A-AFE7-AD18183889EDQ34511512-A7621061-8DF7-4351-ACF8-9BE93E0B3563Q35545820-AE430501-9383-4F31-94C4-79587E5C98F9Q35936126-8A2E1CA0-D95B-41C9-A4AC-22708BC28DCAQ36384541-6710A371-7BCA-45C4-A22B-CE0AC8B88464Q37711653-AEE6CF19-0C0A-42A0-AE93-8B63F6424B97Q38237653-9F1E98F3-C7CF-4CB7-83D3-22DD3D45D817Q38619215-E73C569A-4495-4CDA-BBF2-CE4CE36068C1Q38660283-56CD96D3-CB9E-4305-8266-EC92D2C04B13Q38673039-9E99B7C7-E789-49F3-A21A-3C4322EE9735Q38765507-A277CB5B-D89B-466F-ADCC-260EA2E17773Q39150005-189DB17C-A22B-4902-A834-47F95D3347E6Q39364761-77A99AD6-6E81-4174-8479-AAF5BC4BEC4AQ39599196-68390E85-DF26-4241-AA58-8B98EC253F48Q40099115-0E617D0E-95B6-4187-BE6F-9FBFB8C68468Q40638288-ADB3022A-F9B0-4C1E-BB9A-0E08305B8549Q43857212-D6F9BE35-3B4B-4786-B374-7F93E6743D2EQ44038125-A387197B-5398-45ED-A401-1184AA3EE420Q44664897-1434D398-1432-4AD5-A9DA-C73F19553E23Q47135556-B29EFEE7-8DE1-4242-9012-2926BF0362C5Q48323904-0B5DB1D4-C292-4800-B5A6-E4D9525190CFQ49072822-C38ADC83-C2FA-430D-A297-AD34285C6869
P2860
A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A multicentre randomised phase ...... ncreatic cancer: GEMSAP study.
@ast
A multicentre randomised phase ...... ncreatic cancer: GEMSAP study.
@en
type
label
A multicentre randomised phase ...... ncreatic cancer: GEMSAP study.
@ast
A multicentre randomised phase ...... ncreatic cancer: GEMSAP study.
@en
prefLabel
A multicentre randomised phase ...... ncreatic cancer: GEMSAP study.
@ast
A multicentre randomised phase ...... ncreatic cancer: GEMSAP study.
@en
P2093
P2860
P356
P1476
A multicentre randomised phase ...... ncreatic cancer: GEMSAP study.
@en
P2093
N Sasahira
S Matsubara
P2860
P2888
P304
P356
10.1038/BJC.2012.183
P407
P577
2012-05-03T00:00:00Z